Aggressive Lymphomas
Feature
NICE looks likely to reject use of Kymriah for DLBCL
The U.K. agency issued draft guidance recommending against use of tisagenlecleucel (Kymriah) a month after issuing similar guidance about...
News
CHMP supports new indication for venetoclax
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve a...
News
Stress linked to disease markers in CLL
New research has linked stress levels to markers of progressive disease in patients with chronic lymphocytic leukemia (CLL). Researchers found...
News
NICE rejects DLBCL indication for CAR T-cell therapy
The National Institute for Health and Care Excellence (NICE) has issued a draft guidance saying it cannot recommend tisagenlecleucel (Kymriah) as...
News
Guidelines for proton therapy in mediastinal lymphomas
Proton therapy can help mitigate toxicity in adults with mediastinal lymphomas, but the treatment should only be used in patients expected to...
News
Risks of watchful waiting in follicular lymphoma
A subset of follicular lymphoma (FL) patients managed with watchful waiting are vulnerable to organ dysfunction and transformation, according to...
Guidelines
Best practices defined for proton therapy in mediastinal lymphomas
The limited availability of proton therapy calls for case selection based on a clear understanding of which cases will derive most benefit from...
News from the FDA/CDC
Venetoclax label now includes MRD data
The MURANO trial showed high rates of minimal residual disease negativity in patients treated with the venetoclax combination.
News
MRD data added to venetoclax label
The U.S.
From the Journals
TP53 mutation plus complex karyotype equals poor prognosis
The two markers signaled worse overall survival among mantle cell lymphoma patients.
Latest News
Novartis nabs first CAR T approval in Canada
Health Canada has approved its first chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel (Kymriah).